Compositions and methods for car t cell therapy

Patent metadata

Field	Value
Publication number	US-2020023009-A1
Application number	US-201816489455-A
Country	US
Kind code	A1
Filing date	Feb 28, 2018
Priority date	Feb 28, 2017
Publication date	Jan 23, 2020
Grant date	—

Abstract

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

First claim

1 .- 2 . (canceled)

3 . A method of treatment of a cancer, the method comprising
i) administering to a patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to a targeting moiety by a linker; ii) administering to the patient a CAR T cell composition wherein the CAR T cell composition comprises CAR T cells and wherein the CAR T cells comprise a CAR directed to the targeting moiety; and iii) administering to the patient a folate, a conjugate comprising a folate wherein the conjugate comprising a folate does not comprise a targeting moiety, or an agent that inhibits activation of the CAR T cells.

4 .- 6 . (canceled)

7 . A method of treatment of a cancer, the method comprising
i) administering to a patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to a targeting moiety by a linker, wherein at least a first dose and a second dose of the compound, or the pharmaceutically acceptable salt thereof, are administered to the patient, wherein the first dose and the second dose are different, wherein the second dose of the compound, or the pharmaceutically acceptable salt thereof, is about 2-fold to about 15000-fold greater in amount than the first dose of the compound, or the pharmaceutically acceptable salt thereof; and ii) administering to the patient a CAR T cell composition comprising CAR T cells wherein the CAR T cells comprise a CAR directed to the targeting moiety.

8 . A method of treatment of a cancer, the method comprising
i) administering to a patient a first dose of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to a targeting moiety by a linker; ii) administering to the patient at least a second dose of the compound, or a pharmaceutically acceptable salt thereof, wherein the second dose of the compound, or the pharmaceutically acceptable salt thereof, is at least about 50 percent lower in amount than the first dose of the compound, or the pharmaceutically acceptable salt thereof; and iii) administering to the patient a dose of a CAR T cell composition comprising CAR T cells wherein the CAR T cells comprise a CAR directed to the targeting moiety.

9 .- 12 . (canceled)

Assignees

• Endocyte Inc
• Purdue Research Foundation

Inventors

• Low Philip Stewart
• Chu Haiyan
• Lee Yong Gu
• Lu Yingjuan J
• Leamon Christopher Paul
• Wheeler Ii Leroy W

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2319/033

  containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• C07K16/30

  from tumour cells · CPC title